A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy was written by Gouni, Sushanth;Rosenthal, Allison C.;Crombie, Jennifer L.;Ip, Andrew;Kamdar, Manali K.;Hess, Brian;Feng, Lei;Watson, Grace;Ayers, Amy;Neelapu, Sattva S.;Khurana, Arushi;Lin, Yi;Iqbal, Madiha;Merryman, Reid W.;Strati, Paolo. And the article was included in Blood Advances in 2022.Quality Control of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:
Polatuzumab vedotin (PV) is an antibody-drug conjugate targeting CD79b that is approved for patients with relapsed/refractory large B-cell lymphoma (LBCL). Patients who relapse after chimeric antigen receptor (CAR) T-cell therapy were not included in the registration study, and reports of PV use after CAR T cells are limited. This multicenter retrospective anal. included patients with LBCL who relapsed or progressed after CAR T-cell therapy and subsequently received PV with or without rituximab and bendamustine between July 2019 and May 2021. Response to treatment and progression were assessed based on the 2014 Lugano criteria. Fifty-seven patients were included in the study: 18 (32) patients were primary refractory to CAR T-cell therapy, and 34 (60) patients received PV-based therapy immediately after CAR T-cell therapy. PV was combined with rituximab in 54 (95) patients and administered with bendamustine in 35 (61) patients. A response was achieved in 25 (44) patients, including complete remission in 8 (14). No significant association between baseline characteristics and response was observed After a median follow-up of 47 wk (95confidence interval [CI], 40-54), 46 (81) patients had disease progression or died, and the median progression-free survival was 10 wk (95CI, 5-15). On a multivariate anal., bone marrow involvement (hazard ratio, 5.2; 95CI, 1.8-15; P = .003) and elevated lactate dehydrogenase levels (hazard ratio, 5.0; 95CI, 1.4-16; P = .01) were associated with shorter progression-free survival. Studies aimed at better characterizing the intrinsic mechanism of resistance and identifying optimal consolidation strategies for these patients are warranted. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Quality Control of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Quality Control of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem